Supplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Year: 2024
Type: supplementary-materials
Abstract: Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
Authors: Andrew L. Coveler, Matthew J. Reilley, Mark Zalupski, Teresa Macarulla, Christos Fountzilas, Mariano Ponz-Sarvisé, Adnan Nagrial, Nataliya V. Uboha, Sophia Frentzas, Michael Overman, Anne Noonan, Wells A. Messersmith, Nick Pavlakis, Niharika B. Mettu, Ina Bisha, Ying Wang, Paul Smith, Elina Murtomaki, Agata A. Bielska, Veronique Bragulat, Zachary A. Cooper, Rakesh Kumar, David R. Spigel
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403437097